Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-201 in advanced HER2+ solid tumors
NCT05678205Phase 2Withdrawn
- Sponsor
- Artiva Biotherapeutics, Inc.
- Start
- Aug 2023
- Primary completion
- Apr 2027
- Modality
- Recombinant Proteins and Enzymes, CAR-NK Cells
- Countries
- 2
01
Overview
A Phase 2 trial of AB-201 in breast cancer, gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Artiva Biotherapeutics, Inc.. Planned start Aug 2023; status: withdrawn.
02
Drugs
AB-201
03
Conditions
breast cancergastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05678205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05678205.